Market Overview:
The global neurodegenerative drugs market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of neurodegenerative diseases, rising geriatric population, and technological advancements in the field of neurology. Based on type, the global neurodegenerative drugs market is segmented into NMDA receptor antagonists, serotonin reuptake inhibitors (SSRIs), dopamine inhibitors, and others. The NMDA receptor antagonists segment is expected to grow at a CAGR of 8% from 2018 to 2030. This growth can be attributed to the increasing prevalence of Alzheimer’s disease and other neurological disorders caused by excitotoxicity mediated by overactivation of glutamate receptors. Based on application, the global neurodegenerative drugs market is segmented into Parkinson’s disease, Huntington disease, amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease.
Product Definition:
Neurodegenerative drugs are medications that are used to treat neurodegenerative diseases. These drugs help to slow down or stop the progression of the disease. They can also improve symptoms and quality of life for patients.
NMDA:
N-methyl-D-aspartate (NMDA) is an amino acid found in the body. It is a noncompetitive inhibitor of glutamate at the NMDAR receptor and it's used as an excitatory neurotransmitter. The rise in research for neurodegenerative diseases such as Alzheimer’s, Parkinson’s disease, & Epilepsy has led to significant growth of NMDA over the past few years.
SSRIs:
SSRIs are selective serotonin receptor inhibitors. They are used as the first line of therapy for depression and anxiety disorders. SSRIs block the re-absorption of serotonin by certain nerve cells in the brain, which enhances or increases serotonergic activity in the brain. Serotonin is an important chemical for both mood and memory enhancement.
Application Insights:
The other application segment covers the Parkinson¢â‚¬â„¢s disease segment which held the largest market share in 2017. The growing prevalence of Parkinson's disease, coupled with rising healthcare expenditure, is anticipated to propel the growth of this segment during the forecast period.
The Alzheimer¢â‚¬â„¢s disease application is expected to witness lucrative growth over the forecast period owing to increasing awareness about neurodegenerative disorders and government initiatives encouraging people aged 60 years and above to undergo regular check-ups for early detection of symptoms. According to a study published by CDC in 2012, it was estimated that more than 4 million Americans were suffering from Alzheimer's disease; however, only half of them were receiving treatment despite being diagnosed at an early stage. This fact is projected to boost product demand in near future.
Rising prevalence of neurological disorders and increasing government initiatives encouraging people aged 60 years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, availability of effective treatment methods, high healthcare expenditure levels, and rising awareness about neurodegenerative disorders are some factors attributing to its largest share. Moreover, increasing R&D activities by major players for development of novel drugs is also expected to drive growth over the forecast period.
Asia Pacific is estimated to witness lucrative CAGR during the forecast period owing to growing medical tourism industry in emerging economies such as India and China along with other South East Asian countries. In addition, favorable government initiatives for research collaborations with western nations are also likely boost regional growth over the next eight years.
Growth Factors:
- Increasing prevalence of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
- Growing awareness about the available treatment options for neurodegenerative diseases.
- Rising demand for better and more effective treatments for neurodegenerative diseases.
- increasing research and development activities in the field of neurodegenerative drugs market . 5 . Technological advancements in the field of neurology that are expected to lead to the development of novel therapies for treating various forms of neurodegeneration
Scope Of The Report
Report Attributes
Report Details
Report Title
Neurodegenerative Drugs Market Research Report
By Type
NMDA, SSRIs, Dopamine Inhibitors
By Application
Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease
By Companies
Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, Livzon Pharmaceutical, Haisco Pharmaceutical, Jingxin Pharmaceutical, Dongcheng Biochemicals, Hisun Pharmaceutical, Luye Pharma, Ark Pharmaceutical, Kanghong Pharmaceutical, Huahai Pharmaceutical, BORA PHARMACEUTICALS
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
219
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Neurodegenerative Drugs Market Report Segments:
The global Neurodegenerative Drugs market is segmented on the basis of:
Types
NMDA, SSRIs, Dopamine Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Merck Serono
- Biogen Idec
- TEVA
- UCB
- Boehringer Ingelheim
- Sanofi
- GlaxoSmithKline
- Livzon Pharmaceutical
- Haisco Pharmaceutical
- Jingxin Pharmaceutical
- Dongcheng Biochemicals
- Hisun Pharmaceutical
- Luye Pharma
- Ark Pharmaceutical
- Kanghong Pharmaceutical
- Huahai Pharmaceutical
- BORA PHARMACEUTICALS
Highlights of The Neurodegenerative Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NMDA
- SSRIs
- Dopamine Inhibitors
- By Application:
- Parkinson’s Disease
- Huntington Disease
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neurodegenerative Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neurodegenerative drugs are medications that slow or stop the progression of diseases that damage the brain and spinal cord.
Some of the major companies in the neurodegenerative drugs market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, Livzon Pharmaceutical, Haisco Pharmaceutical, Jingxin Pharmaceutical, Dongcheng Biochemicals, Hisun Pharmaceutical, Luye Pharma, Ark Pharmaceutical, Kanghong Pharmaceutical, Huahai Pharmaceutical, BORA PHARMACEUTICALS.
The neurodegenerative drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neurodegenerative Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neurodegenerative Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neurodegenerative Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neurodegenerative Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neurodegenerative Drugs Market Size & Forecast, 2018-2028
4.5.1 Neurodegenerative Drugs Market Size and Y-o-Y Growth
4.5.2 Neurodegenerative Drugs Market Absolute $ Opportunity
Chapter 5 Global Neurodegenerative Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Neurodegenerative Drugs Market Size Forecast by Type
5.2.1 NMDA
5.2.2 SSRIs
5.2.3 Dopamine Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Neurodegenerative Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Neurodegenerative Drugs Market Size Forecast by Applications
6.2.1 Parkinson’s Disease
6.2.2 Huntington Disease
6.2.3 Amyotrophic Lateral Sclerosis
6.2.4 Alzheimer’s Disease
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Neurodegenerative Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neurodegenerative Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Neurodegenerative Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Neurodegenerative Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Neurodegenerative Drugs Market Size Forecast by Type
9.6.1 NMDA
9.6.2 SSRIs
9.6.3 Dopamine Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Neurodegenerative Drugs Market Size Forecast by Applications
9.10.1 Parkinson’s Disease
9.10.2 Huntington Disease
9.10.3 Amyotrophic Lateral Sclerosis
9.10.4 Alzheimer’s Disease
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Neurodegenerative Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Neurodegenerative Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Neurodegenerative Drugs Market Size Forecast by Type
10.6.1 NMDA
10.6.2 SSRIs
10.6.3 Dopamine Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Neurodegenerative Drugs Market Size Forecast by Applications
10.10.1 Parkinson’s Disease
10.10.2 Huntington Disease
10.10.3 Amyotrophic Lateral Sclerosis
10.10.4 Alzheimer’s Disease
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Neurodegenerative Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Neurodegenerative Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Neurodegenerative Drugs Market Size Forecast by Type
11.6.1 NMDA
11.6.2 SSRIs
11.6.3 Dopamine Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Neurodegenerative Drugs Market Size Forecast by Applications
11.10.1 Parkinson’s Disease
11.10.2 Huntington Disease
11.10.3 Amyotrophic Lateral Sclerosis
11.10.4 Alzheimer’s Disease
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Neurodegenerative Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Neurodegenerative Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Neurodegenerative Drugs Market Size Forecast by Type
12.6.1 NMDA
12.6.2 SSRIs
12.6.3 Dopamine Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Neurodegenerative Drugs Market Size Forecast by Applications
12.10.1 Parkinson’s Disease
12.10.2 Huntington Disease
12.10.3 Amyotrophic Lateral Sclerosis
12.10.4 Alzheimer’s Disease
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Neurodegenerative Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Neurodegenerative Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Neurodegenerative Drugs Market Size Forecast by Type
13.6.1 NMDA
13.6.2 SSRIs
13.6.3 Dopamine Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Neurodegenerative Drugs Market Size Forecast by Applications
13.10.1 Parkinson’s Disease
13.10.2 Huntington Disease
13.10.3 Amyotrophic Lateral Sclerosis
13.10.4 Alzheimer’s Disease
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Neurodegenerative Drugs Market: Competitive Dashboard
14.2 Global Neurodegenerative Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 Merck Serono
14.3.4 Biogen Idec
14.3.5 TEVA
14.3.6 UCB
14.3.7 Boehringer Ingelheim
14.3.8 Sanofi
14.3.9 GlaxoSmithKline
14.3.10 Livzon Pharmaceutical
14.3.11 Haisco Pharmaceutical
14.3.12 Jingxin Pharmaceutical
14.3.13 Dongcheng Biochemicals
14.3.14 Hisun Pharmaceutical
14.3.15 Luye Pharma
14.3.16 Ark Pharmaceutical
14.3.17 Kanghong Pharmaceutical
14.3.18 Huahai Pharmaceutical
14.3.19 BORA PHARMACEUTICALS
